Company History - Hikal
YEAR EVENTS
1988 - The Company was incorporated on 8th July, with the objective
of
carrying on the business of manufacture and marketing of
chemicals, intermediates, dyes, pharmaceuticals and
pesticides.
- Hikal Chemical Industries Limited (HCIL), jointly promoted by
Surajmukhi Investment and Finance Limited, a wholly owned
subsidiary of Kalyani Steels Limited and the Hiremath family.
- The period from 1988 to 1991 was utilised in setting up the
manufacturing facilities at Mahad over land admeasuring 27004
square metres.
1990 - On 28th February, HCIL became a deemed public company under
the
provisions of Section 43 A of the Companies Act, 1956, and a
fresh Certificate of Incorporation was obtained from the
Registrar of Companies.
- The Company also proposes to enter the business of
agrochemicals,
more specifically pesticides, and commence production of
Metoxuron (used as a wheat herbicide) and Metamitron (used as
a
sugar beet herbicide).
1991 - The Company has issued 1,50,000 shares of Rs.10/- each to
Hiremath Chemicals Limited in lieu of technical know-how and
engineering in the year.
- The Memoranum of Understanding (MOU) dated 3rd January, valid
for
a period of 7 years, between Hikal Chemical Industries Ltd.
and Hiremath Chemicals Ltd. covers transfer of technology and
technical assistance for Meta chloro aniline, 3,4 DCNB and
paracumidine.
1993 - In December, Sumitomo Corporation, Japan, one of the world's
largest trading houses, with assets of U.S. $ 46,402 million
and
Net Income of U.S. $ 176 million acquired an equity stake in
the
Company. Sumitomo has interests in commodities, industrial
and
consumer goods.
- Hikal was the first chemical company in India in which
Sumitomo
Corpn. has taken equity in 1993 with a 3.62% share.
- Agreement dated 30th September, entered into between the
Company
and Mr. Jai. Hiremath on his appointment as the Managing
Director
of the Company.
1994 - The Company subsequently became full fledged Public Limited
Company by passing a special resolution in the E.G.M. held on
7th
July. Revised certificate of incorporation has been obtained
on
16th September.
- In order to part finance the expansion-cum-diversification
programme, the company had successfully made a public issue
of
7,50,000 equity shares of Rs.10/- each at a premium of Rs.
40/-
in October. The public issue received over whelming response
from the investors and the offer made to the public was
oversubscribed by 21.48 times.
1995 - The company has successfully completed the expansion of the
Meta
Chloro Aniline and Para Cumidine Plants.
- The company has also undertaken diversification in the field
of
Agro Chemicals and has started production of Metoxuron and
has
entered into a long term exclusive contract with Searle
(India)
Ltd.
- The company issued 593926 bonus shares in the ratio of 1
equity
share for every 2 equity shares held in July by apitalising
free
reserves of Rs. 59.39 lacs.
- The company issued 445722 equity shares of Rs. 10 each and
22500
equity shares of Rs. 10 each for cash at par on rights and
preferential basis respectively in July.
- New products will be introduced to improve the profitability
of the Company.
1996 - Metoxuron plant was successfully commissioned and after trial
runs commercial production commenced during March.
- The company maintained the highest standards of safety.
Effective effluent treatment plant & environment care were
the
top priorities.
1997 - Hikal Chemicals Industries Limited is engaged in the
production
of chemicals used by the pharmaceuticals, agro chemicals and
dye industries.
- The company has also launched Metoxuron a technical wheat
herbicide. For this product the company has entered into a
agreement with Searle India, which will buy it for a period
of
five years.
- The company has issued 4,00,000 14% Non Convertible
Cumulative
Redeemable Preference Shares of Rs. 100/- each on 28th
October,
for 3 years to IDBI Bank Ltd.
- The company has allotted 14,66,700 equity shares of Rs. 10/-
each, at premium of Rs. 35/- on 26th December, to promoters &
Sumitomo Corporation, Japan on Preferential allotment basis.
1998 - The company has appointed a representative in England to
indentify our efforts to increase export.
- The company has entered into a 10 year agreement with Merck &
Co.
Inc., U.S.A. for exclusive supply of Thiabendazole on 100%
buy
back arrangement.
1999 - The promoters of Hikal Chemicals Industries Ltd (HCIL) and
the
Kalyani group, through their subsidiary, are making an
unconditional cash open offer to all equity shareholders of
Hikal Chemicals Industries Ltd (HCIL) to purchase 50,300
shares
of Rs 10 each at Rs 45 per fully paid up share.
- Hikal is the only company in the world which manufactures TBZ
and
the plant has been set up with the technical support of Merck
&
Co Inc.
- Hikal is also in talks for joint ventures (outside Hikal)
with
pharmaceutical and agrochemical multinationals (MNCs) where
the
technology for new molecules would be transferred to the
venture by the MNC in exchange for equity.
- The company has undertaken several measures to improve the
profitability of the Mahad unit. The company has started
manufacturing and exporting Isoproturon, which is a forward
integration of its main product Para Cumidine. Mahad unit
received ISO 9000 certification.
2000 - Hikal Chemical Industries Ltd. has informed the BSE that it
will
issue one bonus share for every one share held by its
shareholders.
- Hikal Chemical Industries Ltd. has changed its name to Hikal
Ltd.
The Change of name reflects the company's intentions to
diversify
into agro chemicals, pharmaceuticals, information technology
and
biotech.
- Hikal Chemical Industries Ltd., the only global producer of TBZ
has been
awarded the British Safety Council award for world class
health, safety and
environmental standards at their Taloja plant near Mumbai.
2002
-Appoints Mr Bimal Kishore Raizada as the Additional Director of the
company.
2003
-Board approves for the issue of Bonus shares.
-Signs agreement with US based pharmaceutical company to supply
Gabapentin, a $2 billion anti-depressant that is going off patent.
-Enters into Long term supply agreement with a leading Corp
protection company in USA for supply of new generation agrochemical.
2004
-Hikal Limited has informed that the Company had applied for
delisting of its securities from Ahmedabad Stock Exchange and Pune
Stock Exchange. Pune Stock Exchange Ltd. has informed the exchange
that it has approved company's request and the equity shares of Hikal
Ltd. are delisted from Pune Stock Exchange Ltd. wef January 16, 2004.
-Hikal enters into long term agreement with Bayer CropScience AG
-Hikal acquires European Pharma Distributor Marsing & Co.
-Hikal takes over Danish co
2005
-Hikal Ltd has entered into a long term agreement with a leading
American Company, Crompton Corporation, USA, for manufacture & supply
of a New Generation crop protection product.
-Hikal joins Pfizer's epilepsy drug marketing row in US.
2006
-Hikal Ltd, manufacturer of pharmaceutical and agrochemical
ingredients and intermediates, has signed an agreement with Germany's
third-largest chemical company Degussa for supplying pharmaceutical
intermediates and active pharma ingredients (APIs).
-The Registered Office of the Company has been shifted from 6, Nawab
Building , 327, Dr. D. N. Road, Fort, Mumbai-400 001 to 717/718 Maker
Chamber V, 7th Floor, Nairman Point, Mumbai-400 021.
2011
-The Board has appointed Dr. Wolfgang Welter as an Additional
Director.
-The prestigious “Hikal Cup” Corporate Tennis Tournament for the year
2011 was played at the Bombay Gymkhana Tennis Courts.
2012
-Hikal Board recommends Final Dividend on the Equity Share Capital @
(60%) Rs. 6/- (Rupees six only) per Equity Share, nominal value of
Rs. 10/- each
2013
-Hikal’s Pharmaceutical Manufacturing Site in Gujarat, India received
US FDA Approval.
-Hikal Ltd Board recommends Dividend on Equity Share Capital @ 25%
[Rs. 2.50 per equity share, (nominal value of Rs. 10 each)] for
financial year 2012-13
-Hikal signs a long term supply agreement with a leading global
Biopharmaceutical Company
2014
-Hikal Ltd Board recommends Dividend on Equity Share Capital [Rs.
4.5/- per equity share, (nominal value of Rs. 10/- each) [including
interim dividend of 20% (Rs. 2/- per equity share) declared / paid
-Hikal Completed successful EDQM Audit of its Bangalore facility
2015
-Hikal has splits its face value from Rs. 10 to Rs. 2